Instruction manual

Contents

1. Intended Use	1
2. Clinical Applications and Principle of the Assay	1
3. Kit Contents	2
4. Storage and Shelf Life	2
5. Precautions of Use	3
6. Sample Collection, Handling and Storage	3
7. Assay Procedure	4
8. Qualitative Interpretation	5
9. Technical Data	6
10. Performance Data	6-7
11. Literature	7
A : Pipetting scheme	8
B : Test Procedure	9

002 : 2007-08-28 REF 3102 ENA-6S

1. Intended Use

AESKULISA ENA-6S is a solid phase enzyme immunoassay for the combined qualitative detection of IgG antibodies against six cellular and nuclear antigens in human serum. Each well is coated with recombinant SS-B, SS-A 52 kDa, ScI 70, Jo-1 and highly purified native human snRNP/Sm, Sm and SS-A 60 kDa.

The assay is a tool in the differential diagnosis of systemic rheumatic diseases.

2. Clinical Application and Principle of the Assay

Anti-nuclear antibodies (ANA) are an important tool for the differential diagnosis of systemic rheumatic diseases. Indirect immunofluorescence test (IFT) on eucaryotic cells like HeLa has been the established method for the detection of ANAs. Single antibody specificities are distinguished by fluorescence patterns but more specific testing by ELISAs employing the target antigens (see AESKULISA ENA 6-Pro e.g.) are available too for a simple and reliable differentiation of ANAs.

ANAs are especially found in active and inactive systemic lupus erythematosus (SLE), mixed connective tissue diseases (MCTD), scleroderma, Sjögren's syndrome and polymyositis.

ANA Antibodies against:

- Sm (Smith antigen) are directed against core proteins (B, B`, D1-D3, E, F, G) of small nuclear ribonucleoproteins (snRNPs). Anti-Sm as well as antibodies against double stranded DNA (dsDNA) are highly specific for SLE and thus are included in diagnostic and classification criteria for SLE.
- snRNP/Sm complex are directed against Sm and U1 snRNP proteins (70 kDa, A and C). They occur in SLE, Sjögren`s syndrome, scleroderma and polymyositis.
- SS-A (Ro; soluble cytomplasmic and/or nuclear ribonucleoproteins of 52 kDa and 60 kDa) and antibodies against SS-B (La; 48 kDa protein associated with RNA polymerase III) are mainly found in high titers for primary and secondary Sjögren's syndrome but also in SLE, congenital heartblock and neonatal lupus.
- Scl-70 are directed against DNA-topoisomerase I. They are highly specific for systemic scleroderma and give a hint for a severe course.
- Jo-1 are directed against histidyl-tRNA synthetase (cytoplasmic protein involved in protein biosynthesis) and are found in 20-40 % of patients with polymyositis and dermatomyositis.

Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The rate of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

Page 1 of 9 002 : 2007-08-28 REF 3102 ENA-6S

3. Kit Contents

To be reconstituted:

5x Sample Buffer 1 vial, 20 ml - 5x concentrated (capped white: yellow solution)

Containing: Tris, NaCl, BSA, sodium azide < 0.1% (preservative)

50x Wash Buffer 1 vial, 20 ml - 50x concentrated (capped white: green solution)

Containing: Tris, NaCl, Tween 20, sodium azide < 0.1% (preservative)

Ready to use:

Negative Control 1 vial, 1.5 ml (capped green: colorless solution)

Containing: Human serum (diluted), sodium azide (preservative)

Positive Control 1 vial, 1.5 ml (capped red: yellow solution)

Containing: Human serum (diluted), sodium azide (preservative)

Cut-off Calibrator 1 vial, 1.5 ml (capped blue: yellow solution)

Containing: Human serum (diluted), sodium azide (preservative)

Conjugate 1 vial,15 ml lgG (capped blue: blue solution),

Containing: Anti-human immunoglobulins conjugated to horseradish peroxidase

TMB Substrate 1 vial, 15 ml (capped black)

Containing: Stabilized TMB/H2O2

Stop Solution 1 vial, 15 ml (capped white: colorless solution)

Containing: 1M Hydrochloric Acid

Microtiterplate 12x8 well strips with breakaway microwells

Coating see paragraph 1

Material required but not provided:

Microtiter plate reader 450 nm reading filter and optional 620 nm reference filter (600-690 nm). Glass ware(cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 μ l) or adjustable multipipette (100-1000ml). Microplate washing device (300 μ l repeating or multichannel pipette or automated system), adsorbent paper.

Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).

4. Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable for 1 month at 4°C/39°F, at least. **Reagents and the microplate shall** be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.

Page 2 of 9 002 : 2007-08-28 REF 3102 ENA-6S

5. Precautions of Use

5.1 Health hazard data

This product is for **IN VITRO DIAGNOSTIC USE** only. Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of normal use, refer to the following for maximum safety:

Recommendations and precautions

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves.

WARNING! Calibrators, Controls and Buffers contain sodium azide (NaN₃) as a preservative. NaN₃ may be toxic if ingested or adsorbed by skin or eyes. NaN₃ may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

Do not smoke, eat or drink when manipulating the kit.

Do not pipette by mouth.

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

5.2 General directions for use

Do not mix or substitute reagents or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

Incubation: We recommend test performance at 30°C/86°F for automated systems.

Never expose components to higher temperature than 37°C/98.6 °F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.

6. Sample Collection, Handling and Storage

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements.

Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes. After separation, the serum samples should be used immediately, respectively stored tightly closed at $2-8^{\circ}\text{C}/35-46^{\circ}\text{F}$ up to three days, or frozen at $-20^{\circ}\text{C}/-4^{\circ}\text{F}$ for longer periods.

Page 3 of 9 002 : 2007-08-28 REF 3102 ENA-6S

7. Assay Procedure

7.1 Preparations prior to pipetting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml). Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

Samples:

Dilute serum samples 1:101 with sample buffer (1x) e.g. 1000 µl sample buffer (1x) + 10 µl serum. Mix well!

Washing:

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells e.g. 4 ml concentrate plus 196 ml distilled water.

Automated washing:

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

Manual washing:

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

Microplates:

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

7.2 Work flow

For pipetting scheme see Annex A, for the test procedure see Annex B We recommend pipetting samples and calibrators in duplicate.

- Pipette 100 µl of each patient's diluted serum into the designated microwells.
- Pipette 100 µl cut-off calibrator and negative and positive controls into the designated wells.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 μl conjugate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl TMB substrate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.
- Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
- Incubate 5 minutes minimum.
- Agitate plate carefully for 5 sec.
- Read absorbance at 450 nm (optionally 450/620 nm) within 30 minutes.

Page 4 of 9 002 : 2007-08-28 REF 3102 ENA-6S

8. Qualitative Interpretation

Read the optical density of the cut-off calibrator and the patient samples. Compare patient ODs with the OD of the cut-off calibrator. For qualitative interpretation we recommend to consider sera within a range of 20% around the cut-off value as equivocal. All samples with higher ODs are considered positive, samples with lower ODs are considered negative.

Negative: OD patient < 0.8 x OD cut-off

Equivocal: $0.8 \times OD_{cut-off} \le OD_{patient} \le 1.2 \times OD_{cut-off}$

Positive OD patient > 1.2 x OD cut-off

Calibrators	O.D. 450/620 nm	CV % (Variation)
Negative Control	0.033	2.7
Cut-off Calibrator	0.550	1.5
Positive Control	1.369	0.9

Example of interpretation

We recommend pipetting cut-off calibrator in parallel for each run.

Cut-off calibrator	Patient sample	OD Quotient	Interpretation
0.35 OD	0.25 OD	0.75	Negative
0.35 OD	0.40 OD	1.14	Equivocal
0.35 OD	0.56 OD	1.60	Positive
0.35 OD	1.75 OD	5.00	Positive

Do not use this example for interpreting patients results!

We recommend to retest samples, that are borderline. For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an in-house Quality Control by using own controls and/or internal pooled sera, as foreseen by EU regulations.

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

For semi-quantification of the results, each patient-OD value can be expressed by the Index-Value. The Index-Value is calculated by dividing the patient-OD by the cut-off OD:

Index Value = $\frac{\text{OD (patient sample)}}{\text{OD (cut-off calibrator)}}$

Negative: Index Value < 0.8 Equivocal: 0.8 ≤ Index Value ≤ 1.2 Positive: Index Value > 1.2

Page 5 of 9 002 : 2007-08-28 REF 3102 ENA-6S

9. Technical Data

Sample material: serum

Sample volume: 10 μl of sample diluted 1:101 with 1x sample buffer

Total incubation time: 90 minutes at 20-32°C/68-89.6°F

Storage: at 2-8°C/35-46°F use original vials, only

Number of determinations: 96 tests


10. Performance Data

10.1 Specificity and sensitivity

The microplate is coated with a mixture of highly purified and/or recombinant antigens (SS-A, SS-B, snRNP/Sm, Sm, ScI-70, Jo-1). No crossreactivities to other autoantigens have been found. ANA are not specific for SLE but are found in variety of rheumatic diseases. Detection of ANA is a very sensitive marker for an active SLE and is positive in >99% of all cases. The data has been aquired with the AESKULISA ENA-6S (REF7102).

Correlation:

The comparability of performance data was assessed with 50 sera tested on both, *AESKULISA* 7102 and *AESKULISA* 3102. A linear regression analysis of the two products showed that the two products are equivalent. Included in these sera are 22 sera close to cut-off.



Page 6 of 9 002 : 2007-08-28 REF 3102 ENA-6S

10.2 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

		measured	expected	
Sample	Dilution	concentration	concentration	Recovery
No.	Factor	(U/ml)	(U/ml)	(%)
1	1 / 100	3.2	3.5	91.4
	1 / 200	1.7	1.8	94.4
	1 / 400	1.0	0.9	107.9
	1 / 800	0.5	0.4	102.3
2	1 / 100	1.5	1.6	93.8
	1 / 200	0.8	0.8	96.6
	1 / 400	0.4	0.4	100.0
	1 / 800	0.2	0.2	100.0

10.3 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve.

I	ntra-Assa	у
Sample	Mean	CV
No.	(OD-Ratio)	(%)
1	3.1	0.8
2	2.3	1.0
3	1.5	1.1

li	nter-Assa	у
Sample	Mean	CV
No.	(OD-Ratio)	(%)
1	3.1	0.7
2	2.2	0.5
3	1.4	1.4

10.4 Calibration

The AESKULISA ENA-6S is calibrated against reference sera from the CDC Atlanta (Centers for Disease Control and Prevention).

11. Bibliographie

1. Antinuclear antibody.

The Lancet 1984, Sept. 15: 611-13.

2. Froelich CH, Wallmann H, Skosey JL and Teodorescu M.

Clinical value of an integrated ELISA system for the detection of 6 autoantibodies.. The Journal of Rheumatology 1990; 17 (2): 192-200.

3. Mierau R, Genth E.

Autoantikörper bei systemischem Lupus erythematodes und verwandten Erkrankungen In: Thomas L. (Hrsg.) Labor und Diagnose.

TH-Books, Frankfurt, 1998, 5. Auflage: 843-851.

4. Schmolke M, Oppermann M, Helmke K, Guder WG.

Antibody determination against ENA- a challenge for the routine laboratory. Poster P59, 5 th Dresden Symposium on Autoantibodies, 2000.

ANNEX A: Pipetting scheme


We suggest pipetting calibrators, controls and samples as follows:


	1	2	3	4	5	6	7	8	9	10	11	12
Α	NC	P2										
В	NC	P2										
С	CC	P3										
D	CC	P3										
Ε	PC											
F	PC											
G	P1											
Н	P1											


CC: Cut-off calibrator PC: positive control NC: negative control

P1: patient 1 P2: patient 2 P3: patient 3

Annex B: Test Procedure







Assay/Test:			II .	Incubation / Inkub. :	nkub. :	<u></u>	ш 	min	Date/ Datum:)atum:		
Temperature/Temperatur:oF	H _o		J.	- \		.5	m 	imi .	Signatı	Signature/Unterschrift:.	hrift:	
					,	3.	E [uim.		•		
1 2 3 4	В		4		5	9	7	∞	6	10	11	12
Negative Control 0 U/ ml												
Negative Control 0 U/ ml												
Cut off calibrator 15 U/ ml												
Cut off calibrator 15 U/ ml												
Positive Control 100 U/ ml												
Positive Control 100 U/ ml												
AESK U.Diagnostics GmbH 55234 Wendelsheim - Mikroforum Ring 2, Germany Phone: + 49-6734-96270, Fax: + 49-6734-962727	3mbH 55234 Wendelsheim - Mikrofc	34 Wendelsheim - Mikrofc	heim - Mikrofa	rofc	rum R	ing 2, Germ	any Phone	e: + 49-673	4-96270, F	ax: + 49-67	34-962727	

	♦ Diagnosi in vitro	◆ For in vitro diagnostic use
IVD	 Pour diagnostic in vitro 	 Para uso diagnóstico in vitro
ן שעון	◆ In Vitro Diagnostikum	♦ In Vitro Διαγνωστικό μέσο
	 Para uso Diagnóstico in vitro 	
	♦ Numero d'ordine	◆ Cataloge number
DEE	♦ Référence Catalogue	 Numéro de catálogo
REF	◆ Bestellnummer	◆ Αριθμός παραγγελίας
	 Número de catálogo 	, ,
	Descrizione lotto	♦ Lot
	◆ Lot	♦ Lote
LOT	◆ Chargen Bezeichnung	Χαρακτηρισμός παρτίδας
	◆ Lote	 ▼ Λαρακτηριόμος παρτίδας
		A FO De desette e et Ocufernite
	◆ Conformità europea	◆ EC Declaration of Conformity
C€	Déclaration CE de Conformité	Declaración CE de Conformidad
	♦ Europäische Konformität	◆ Ευρωπαϊκή συμφωνία
	◆ Déclaração CE de Conformidade	
	♦ 96 determinazioni	♦ 96 tests
\96/	♦ 96 tests	♦ 96 pruebas
	♦ 96 Bestimmungen	◆ 96 προσδιορισμοί
	♦ 96 Testes	
	♦ Rispettare le istruzioni per l'uso	♦ See instructions for use
→	♦ Voir les instructions d'utilisation	♦ Ver las instrucciones de uso
	Gebrauchsanweisung beachten	 Λάβετε υπόψη τις οδηγίες χρήσης
	◆ Ver as instrucões de uso	
_	Da utilizzarsi entro	♦ Use by
	♦ Utilise avant le	♦ Utilizar antes de
<u>2 </u>	♦ Verwendbar bis	 ▼ Οιπεδι δίπες de ♦ Χρήση μέχρι
	Verwendbar bis Utilizar antes de	4 Mailou heVbi
∩ ,-+8°C	♦ Conservare a 2-8°C	 ◆ Store at 2-8°C (35-46°F)
🕍 🤼	♦ Conserver à 2-8°C	◆ Conservar a 2-8°C
+2°C-	◆ Lagerung bei 2-8°C	♦ Φυλάσσεται στους 2-8°C
	◆ Conservar entre 2-8°C	
	♦ Prodotto da	◆ Manufactured by
A A	♦ Fabriqué par	♦ Fabricado por
	◆ Hergestellt von	 ◆ Κατασκευάζεται από
	◆ Fabricado por	* Naraokeougerarano
	◆ Calibratore cut-off	♦ Cut off Calibrator
22.211		
ICO-CAL	♦ Etalon Seuil	◆ Calibrador de cut-off
00 0/ L	Grenzwert Kalibrator Gelibrator de aut eff	 Οριακός ορός Αντιδραστήριο βαθμονόμησης
	◆ Calibrador de cut-off	
	◆ Controllo positivo	◆ Positive Control
C∪VI +	◆ Contrôle Positif	◆ Control Positivo
	◆ Positiv Kontrolle	 Θετικός ορός ελέγχου
	◆ Controlo positivo	- · · · · · · · · · · · · · · · · · · ·
	◆ Controllo negativo	◆ Negative Control
	◆ Contrôle Négatif	◆ Control Negativo
ICONI-	Negativ Kontrolle	 Αρνητικός ορός ελέγχου
	◆ Controlo negativo	· · · · · · · · · · · · · · · · · · ·
	◆ Calibratore	♦ Calibrator
		◆ Calibrator ◆ Calibrador
l CAL II	♦ Etalon	
0/ \L	♦ Kalibrator	 Αντιδραστήριο βαθμονόμησης
	♦ Calibrador	
	♦ Recupero	♦ Recovery
RC	◆ Corrélation	♦ Recuperado
110	 Wiederfindung 	♦ Ανάκτηση
	♦ Recuperacão	
	◆ Coniugato	◆ Conjugate
CONL	♦ Conjugé	♦ Conjugado
CONJ	♦ Konjugat	Σύζευγμα
	♦ Conjugado	
	◆ Micropiastra rivestita	◆ Coated microtiter plate
N.45	◆ Microplague sensibilisée	Microplaca sensibilizada
MP	Beschichtete Mikrotiterplatte	▼ Ινίιστορία σει Ισιδιίτεα α◆ Επικαλυμμένη μικροπλάκα
	•	+ Emikanoppevij pikpolinaka
	Microplaca revestida Distance and architecture at the	A Constant minutes
	Piastra ad aghi rivestita	◆ Coated pinplate
DINID	♦ Pinplate sensibilisée	♦ Pinplate sensibilizada
PINP	♦ Beschichtete Pinplatte	◆ Επικαλυμμένη πλάκα Pin
	♦ Pinplate revestida	
	◆ Tampone di lavaggio	♦ Wash buffer
MA CHE EON	♦ Tampon de Lavage	♦ Solución de lavado
WASHB 50x	 ♦ Waschpuffer 	◆ Ρυθμιστικό διάλυμα πλύσης
	♦ Solução de lavagem	
	◆ Tampone substrato	♦ Substrate buffer
	◆ Substrat	◆ Tampón sustrato
SUB	◆ Substrat ◆ Substratpuffer	•
000		 ◆ Ρυθμιστικό διάλυμα υποστρώματος
	♦ Substrato	
	Reagente bloccante	♦ Stop solution
STOD	♦ Solution d'Arrêt	♦ Solución de parada
STOP	♦ Stopreagenz	 Αντιδραστήριο διακοπής αντίδρασης
	♦ Solução de paragem	
	♦ Tampone campione	♦ Sample buffer
	◆ Tampon Echantillons	
SB 5x	◆ Probenpuffer	 ◆ Ρυθμιστικό διάλυμα δειγμάτων
05 0X	Diluente de amostra	
·		